Article: The use of sex hormones in women with rheumatological diseases

File Download

content.pdf

Links for fulltext
(May Require Subscription)

Scopus: eid_2-s2.0-83255176267
PMID: 22147320

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Obstetrics & Gynaecology: Journal/Magazine Articles

Title	The use of sex hormones in women with rheumatological diseases
Authors	Li, RHW1 Gebbie, AE2 Wong, RWS3 Ng, EHY1 Glasier, AF2 Ho, PC1
Keywords	Arthritis Contraceptives Hormonal Hormone replacement therapy Lupus erythematosus Oral Rheumatic diseases Rheumatoid Systemic
Issue Date	2011
Publisher	Hong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation	Hong Kong Medical Journal, 2011, v. 17 n. 6, p. 487-491 [How to Cite?]
Abstract	A number of rheumatological diseases predominantly affect women of reproductive age. There has always been concern that the use of oestrogen-containing agents such as combined hormonal contraception and hormone therapy might aggravate these conditions. This article reviews the up-to-date evidence regarding the safety of using these agents in women with various rheumatological diseases, with emphasis on systemic lupus erythematosus and rheumatoid arthritis. In the absence of antiphospholipid antibody or other prothrombotic risk factors, combined hormonal contraception is not contra-indicated in most rheumatological conditions including inactive systemic lupus erythematosus. Moreover, hormone therapy is generally not contra-indicated except for women with active systemic lupus erythematosus disease where its effect on disease flare is less clear and individual judgement is required.
Description	Author Chinese name: Raymond HW Li 李幸奐, Ailsa E Gebbie, Raymond WS Wong 黃煥星, Ernest HY Ng 吳鴻裕, Anna F Glasier, PC Ho 何柏松
ISSN	1024-2708 2011 SCImago Journal Rankings: 0.054
References	References in Scopus

DC Field	Value
dc.contributor.author	Li, RHW
dc.contributor.author	Gebbie, AE
dc.contributor.author	Wong, RWS
dc.contributor.author	Ng, EHY
dc.contributor.author	Glasier, AF
dc.contributor.author	Ho, PC
dc.date.accessioned	2012-07-16T09:52:55Z
dc.date.available	2012-07-16T09:52:55Z
dc.date.issued	2011
dc.description.abstract	A number of rheumatological diseases predominantly affect women of reproductive age. There has always been concern that the use of oestrogen-containing agents such as combined hormonal contraception and hormone therapy might aggravate these conditions. This article reviews the up-to-date evidence regarding the safety of using these agents in women with various rheumatological diseases, with emphasis on systemic lupus erythematosus and rheumatoid arthritis. In the absence of antiphospholipid antibody or other prothrombotic risk factors, combined hormonal contraception is not contra-indicated in most rheumatological conditions including inactive systemic lupus erythematosus. Moreover, hormone therapy is generally not contra-indicated except for women with active systemic lupus erythematosus disease where its effect on disease flare is less clear and individual judgement is required.
dc.description.nature	published_or_final_version
dc.description	Author Chinese name: Raymond HW Li 李幸奐, Ailsa E Gebbie, Raymond WS Wong 黃煥星, Ernest HY Ng 吳鴻裕, Anna F Glasier, PC Ho 何柏松
dc.identifier.citation	Hong Kong Medical Journal, 2011, v. 17 n. 6, p. 487-491 [How to Cite?]
dc.identifier.epage	491
dc.identifier.hkuros	201400
dc.identifier.issn	1024-2708 2011 SCImago Journal Rankings: 0.054
dc.identifier.issue	6
dc.identifier.pmid	22147320
dc.identifier.scopus	eid_2-s2.0-83255176267
dc.identifier.spage	487
dc.identifier.uri	http://hdl.handle.net/10722/152944
dc.identifier.volume	17
dc.language	eng
dc.publisher	Hong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
dc.publisher.place	Hong Kong
dc.relation.ispartof	Hong Kong Medical Journal
dc.relation.references	References in Scopus
dc.rights	Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.
dc.rights	Creative Commons: Attribution 3.0 Hong Kong License
dc.subject.mesh	Arthritis, Rheumatoid
dc.subject.mesh	Contraceptives, Oral, Combined
dc.subject.mesh	Contraceptives, Oral, Hormonal
dc.subject.mesh	Hormone Replacement Therapy
dc.subject.mesh	Lupus Erythematosus, Systemic
dc.subject	Arthritis
dc.subject	Contraceptives
dc.subject	Hormonal
dc.subject	Hormone replacement therapy
dc.subject	Lupus erythematosus
dc.subject	Oral
dc.subject	Rheumatic diseases
dc.subject	Rheumatoid
dc.subject	Systemic
dc.title	The use of sex hormones in women with rheumatological diseases
dc.type	Article

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Li, RHW</contributor.author><contributor.author>Gebbie, AE</contributor.author><contributor.author>Wong, RWS</contributor.author><contributor.author>Ng, EHY</contributor.author><contributor.author>Glasier, AF</contributor.author><contributor.author>Ho, PC</contributor.author><date.accessioned>2012-07-16T09:52:55Z</date.accessioned><date.available>2012-07-16T09:52:55Z</date.available><date.issued>2011</date.issued><identifier.citation>Hong Kong Medical Journal, 2011, v. 17 n. 6, p. 487-491</identifier.citation><identifier.issn>1024-2708</identifier.issn><identifier.uri>http://hdl.handle.net/10722/152944</identifier.uri><description>Author Chinese name: Raymond HW Li &#26446;&#24184;&#22864;, Ailsa E Gebbie, Raymond WS Wong &#40643;&#29029;&#26143;, Ernest HY Ng &#21555;&#40251;&#35029;, Anna F Glasier, PC Ho &#20309;&#26575;&#26494;</description><description.abstract>A number of rheumatological diseases predominantly affect women of reproductive age. There has always been concern that the use of oestrogen-containing agents such as combined hormonal contraception and hormone therapy might aggravate these conditions. This article reviews the up-to-date evidence regarding the safety of using these agents in women with various rheumatological diseases, with emphasis on systemic lupus erythematosus and rheumatoid arthritis. In the absence of antiphospholipid antibody or other prothrombotic risk factors, combined hormonal contraception is not contra-indicated in most rheumatological conditions including inactive systemic lupus erythematosus. Moreover, hormone therapy is generally not contra-indicated except for women with active systemic lupus erythematosus disease where its effect on disease flare is less clear and individual judgement is required.</description.abstract><language>eng</language><publisher>Hong Kong Medical Association. The Journal&apos;s web site is located at http://www.hkmj.org/resources/supp.html</publisher><relation.ispartof>Hong Kong Medical Journal</relation.ispartof><rights>Hong Kong Medical Journal. Copyright &#169; Hong Kong Academy of Medicine Press.</rights><rights>Creative Commons: Attribution 3.0 Hong Kong License</rights><subject>Arthritis</subject><subject>Contraceptives</subject><subject>Hormonal</subject><subject>Hormone replacement therapy</subject><subject>Lupus erythematosus</subject><subject>Oral</subject><subject>Rheumatic diseases</subject><subject>Rheumatoid</subject><subject>Systemic</subject><subject.mesh>Arthritis, Rheumatoid</subject.mesh><subject.mesh>Contraceptives, Oral, Combined</subject.mesh><subject.mesh>Contraceptives, Oral, Hormonal</subject.mesh><subject.mesh>Hormone Replacement Therapy</subject.mesh><subject.mesh>Lupus Erythematosus, Systemic</subject.mesh><title>The use of sex hormones in women with rheumatological diseases</title><type>Article</type><description.nature>published_or_final_version</description.nature><identifier.pmid>22147320</identifier.pmid><identifier.scopus>eid_2-s2.0-83255176267</identifier.scopus><identifier.hkuros>201400</identifier.hkuros><relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-83255176267&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references><identifier.volume>17</identifier.volume><identifier.issue>6</identifier.issue><identifier.spage>487</identifier.spage><identifier.epage>491</identifier.epage><publisher.place>Hong Kong</publisher.place><bitstream.url>http://hub.hku.hk/bitstream/10722/152944/1/content.pdf</bitstream.url></item>

Author Affiliations

The University of Hong Kong
Family Planning and Well Women Services
Division of Rheumatology